Intranasal Naloxone
(NS-001)
Access to naloxone is a priority for reducing opioid deaths. Intranasal Naloxone aimed at assisting in acute emergency situations like opioid overdose.
Medical need
During 2022 over 100000 opioid related death occurred in the US
Regulatory requirements
Bioequivalence study –”equal or better”
Phase 3 Study Demonstrates Nasax® Platform Delivers Naloxone Faster and Higher Maximum Concentration Compared to Narcan
- In our phase 3 (n=42) intranasal naloxone study (NS-001), our formulation provided faster delivery and higher mean absorption of naloxone compared to Narcan
- The results of our phase 3 study further validated our Nasax® technology and demonstrate the potential success of NS002
- NS001 is available for partnering